Table 1.
Demographics of study cohort - patients under voriconazole treatment
| Overall (N = 110) | |
|---|---|
| Age at treatment initiation (years) | |
| Mean (SD) | 56 (14) |
| Range | 20 - 78 |
| Gender | |
| Female | 43 (39.1%) |
| Male | 67 (60.9%) |
| Inclusion criteria (hematologic) | |
| Allogeneic hematopoietic cell transplantation | 24 (21.8%) |
| Autologous hematopoietic cell transplantation | 12 (10.9%) |
| Induction chemotherapy for acute leukemia | 66 (60.0%) |
| Salvage treatment for relapsed or refractory acute leukemia | 8 (7.3%) |
| Reason for voriconazole treatment cessation | |
| End of treatment | 47 (42.7%) |
| Death | 28 (25.5%) |
| Clinical worsening/side effects | 26 (23.6%) |
| Lost to follow-up | 4 (3.6%) |
| Still receiving | 4 (3.6%) |
| Unknown | 1 (0.9%) |